Abstract
This study aims to reconfirm the clinical efficacy and related factors of infliximab therapy, the first biological agent introduced to Japanese patients with rheumatoid arthritis (RA). Data of 351 RA patients with infliximab were collected retrospectively from three major centers for management of rheumatic diseases in Japan. Infliximab was infused according to the approved method, and the clinical response was evaluated following 22 weeks of infliximab therapy in 258 patients using the European League Against Rheumatism (EULAR) response criteria. DAS28-CRP (Disease Activity Score including a 28-joint count/C-reactive protein) with a threshold of 4.1 or 2.7 for the high or low disease activity cut-off was also used. A total of 90.3% of patients exhibited high disease activity before infliximab therapy. After 22 weeks of infliximab therapy, the proportions of patients exhibiting high activity, moderate activity, low activity, or in clinical remission were 27.9%, 33.3%, 10.9%, or 27.9%, respectively, thereby indicating good overall efficacy of infliximab therapy. A good or moderate overall response to therapy was achieved in 84.5% of patients. Male sex, rheumatoid factor (RF) negativity, low CRP, lower swollen joint count and a low prednisolone dose were significantly related to the clinical response. Furthermore, male sex, older age, and a high tender joint count had a significant correlation with treatment discontinuation as a result of adverse reactions. In conclusion, we have reconfirmed the effectiveness of infliximab in Japanese patients with RA by using DAS28-CRP and EULAR response criteria. These data will facilitate more efficacious use of this expensive biological agent in the daily practice of rheumatology in Japan.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
GS Firestein (2003) ArticleTitleEvolving concepts of rheumatoid arthritis Nature 423 356–61 Occurrence Handle12748655 Occurrence Handle10.1038/nature01661 Occurrence Handle1:CAS:528:DC%2BD3sXjs1ynu7c%3D
JR Kalden (2002) ArticleTitleExpanding role of biologic agents in rheumatoid arthritis J Rheumatol Suppl 66 27–37 Occurrence Handle12435166 Occurrence Handle1:CAS:528:DC%2BD38XptVGnsLk%3D
AL Weaver (2004) ArticleTitleEfficacy and safety of the anti-TNF biologic agents Modern Rheum 14 IssueID2 101–12 Occurrence Handle1:CAS:528:DC%2BD2cXlt1Glu74%3D
AJ Ostor (2005) ArticleTitleBeyond methotrexate: biologic therapy in rheumatoid arthritis Clin Med 5 IssueID3 222–6 Occurrence Handle16011212
R Maini EW St Clair F Breedveld D Furst J Kalden M Weisman et al. (1999) ArticleTitleInfliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial Lancet 354 1932–9 Occurrence Handle10622295 Occurrence Handle10.1016/S0140-6736(99)05246-0 Occurrence Handle1:CAS:528:DC%2BD3cXit1Oquw%3D%3D
PE Lipsky DM van der Heijde EW St Clair DE Furst FC Breedveld JR Kalden et al. (2000) ArticleTitleInfliximab and methotrexate in the treatment of rheumatoid arthritis N Engl J Med 343 1594–602 Occurrence Handle11096166 Occurrence Handle10.1056/NEJM200011303432202 Occurrence Handle1:CAS:528:DC%2BD3cXovVeltLk%3D
RN Maini FC Breedveld JR Kalden JS Smolen D Furst MH Weisman et al. (2004) ArticleTitleSustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate Arthritis Rheum 50 1051–65 Occurrence Handle15077287 Occurrence Handle10.1002/art.20159 Occurrence Handle1:CAS:528:DC%2BD2cXjslGqsrk%3D
N Miyasaka T Takeuchi K Eguchi (2005) ArticleTitleOfficial Japanese Guidelines for the use of infliximab for rheumatoid arthritis Modern Rheum 15 IssueID1 4–8 Occurrence Handle10.1007/s10165-004-0357-7 Occurrence Handle1:CAS:528:DC%2BD2MXhsV2is7k%3D
Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of DAS28-ESR and DAS28-CRP on threshold values. Ann Rheum Dis 2006;in press [Epub ahead of print]
PL van Riel AM van Gestel LB van de Putte (1996) ArticleTitleDevelopment and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers Br. J Rheumatol 35 IssueIDSuppl 2 4–7 Occurrence Handle8810683
T Takeuchi M Togo A Etoh T Suzuki PA Callegari KE Gilmer (2006) ArticleTitleSafety of infliximab therapy in 4,475 Japanese patients with rheumatoid arthritis: results from post marketing surveillance study (Abstract) Ann Rheum Dis 65 IssueIDSuppl II 503
EW St Clair DM van der Heijde JS Smolen RN Maini JM Bathon P Emery et al. (2004) ArticleTitleCombination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial Arthritis Rheum 50 3432–43 Occurrence Handle15529377 Occurrence Handle10.1002/art.20568 Occurrence Handle1:CAS:528:DC%2BD2cXhtVOqtrvJ
L Klareskog D van der Heijde JP de Jager et al. (2004) ArticleTitleTEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial Lancet 363 IssueID9410 675–81 Occurrence Handle15001324 Occurrence Handle10.1016/S0140-6736(04)15640-7 Occurrence Handle1:CAS:528:DC%2BD2cXhs12jur4%3D
JJ Anderson G Wells AC Verhoeven DT Felson (2000) ArticleTitleFactors predicting response to treatment in rheumatoid arthritis: the importance of disease duration Arthritis Rheum 43 IssueID1 22–9 Occurrence Handle10643696 Occurrence Handle10.1002/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9 Occurrence Handle1:STN:280:DC%2BD3c7gs1Cqsg%3D%3D
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article is available at http://dx.doi.org/10.1007/s10165-007-0562-2.
About this article
Cite this article
Yamanaka, H., Tanaka, Y., Sekiguchi, N. et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol 17, 28–32 (2007). https://doi.org/10.1007/s10165-006-0532-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10165-006-0532-0